¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѼÒÈ­±â¾Ï¿¬±¸ÇÐȸ Á¦19ȸ Ãá°èÇмú´ëȸ : 2024-03-30

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇѼÒÈ­±â¾Ï¿¬±¸ÇÐȸ Á¦19ȸ Ãá°èÇмú´ëȸ : 2024-03-30
±³À°ÀÏÀÚ : 2024-03-30
±³À°Àå¼Ò : ½ºÀ§½º±×·£µå

±³À°ÁÖÁ¦ : ´ëÇѼÒÈ­±â¾Ï¿¬±¸ÇÐȸ Á¦19ȸ Ãá°èÇмú´ëȸ

ÁÖÃÖ±â°ü : ´ëÇѼÒÈ­±âÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѼÒÈ­±â¾Ï¿¬±¸ÇÐȸ

´ã´çÀÚ : ÀÌÇѳª
¿¬¶ôó : 02-313-7710

À̸ÞÀÏ : gicancer@gicancer.or.kr

±³À°Á¾·ù : ³»°ú, ÀÇ·áÀ±¸®ÇÐ

Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡ (ÀÏ¹Ý 5Á¡ / Çʼö 1Á¡)

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 13 ½Ã°£ 30ºÐ

¼¼ºÎ¼ö°­·á : 100,000¿ø  

ºñ°í "±¸ºÐ                                         »çÀüµî·Ï  ÇöÀåµî·Ï

Àü¹®ÀÇ(±³¼ö, ºÀÁ÷ÀÇ, °³¿øÀÇ µî)   5¸¸¿ø 7¸¸¿ø

Àü°øÀÇ, ÀüÀÓÀÇ, ÀϹÝÀÇ           ¹«·á       5¸¸¿ø

Çлý, ÀÇ»ç ¿Ü ±âŸÁ÷±º           ¹«·á 5¸¸¿ø

ÁÂÀå, ¿¬ÀÚ, ÇмúÀ§¿ø                   ¹«·á ¹«·á

¸¸65¼¼ ÀÌ»ó Æò»ýȸ¿ø                   ¹«·á ¹«·á

ºñȸ¿ø(À¯·á)                          8¸¸¿ø 10¸¸¿ø"


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 03¿ù 30ÀÏ Lobby 08:30~09:00 µî·Ï ()

±âŸ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A, B 09:00~09:10 °³È¸»ç ()

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 09:10~09:35 Esophageal/Stomach Cancer ¹ÚÀçÈ£(Ãæ³²ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 09:35~10:00 Colorectal Cancer ±èµ¿¿ì(°í·ÁÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 10:00~10:25 Pancreatobiliary Cancer Á¶ÁßÇö(¿¬¼¼ÀÇ´ë)

ÈÞ½Ä 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A, Lobby 10:25~10:40 ()

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 10:40~11:05 Optimizing Treatment for Oligometastatic Advanced Gastric Cancer: Gastroenterologist¡¯s View (KSGC) ÀüÇÑÁ¶(°í·ÁÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 11:05~11:30 Optimizing Treatment for Oligometastatic Advanced Gastric Cancer: Surgeon¡¯s View (IASGO) Koichi Hayano(Chiba Univ., Japan)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 11:30~11:55 Gastric Outlet Obstruction in Patients with Pancreatobiliary Cancer: Endoscopic Treatment (KSGC) À嵿±â(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 11:55~12:20 Gastric Outlet Obstruction in Patients with Pancreatobiliary Cancer: Surgical Treatment (IASGO) Yosuke Kasai(Kyoto Univ., Japan)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A, B 12:20~12:50 Durvalumab: Real-World Practice in Advanced Biliary Tract Cancer ¹é¿ìÇö(¼­¿ïÀÇ´ë)

±âŸ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A, B 12:50~13:20 ´ëÇѼÒÈ­±â¾Ï¿¬±¸ÇÐȸ ÃÑȸ ()

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 13:20~13:45 Neoadjuvant and Adjuvant Therapy for Cholangiocarcinoma ÀÌÀç¹Î(°í·ÁÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 13:45~14:10 Surgical Approaches for Cholangiocarcinoma À±À¯¼®(¼­¿ïÀÇ´ë ¿Ü°ú)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 14:10~14:35 Therapeutic Approaches in Palliative Care for Cholangiocarcinoma ÀüÁß¿ø(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 14:35~15:00 Advances in Targeted Therapies and Immunotherapy for Cholangiocarcinoma Á¤¹®Àç(¿¬¼¼ÀÇ´ë)

ÈÞ½Ä 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A, Lobby 15:00~15:20 Coffee Break ()

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 15:20~15:30 Real-world evidence of FOLFIRINOX as a first-line salvage treatment in primary chemotherapy-refractory biliary tract cancer ±èÁöÈÆ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 15:30~15:40 Nivolumab versus Pembrolizumab Comparative efficacy of Nivolumab and Pembrolizumab as Palliative therapies in Biliary tract cancer ÀÌŽÂ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 15:40~15:50 Efficacy of third-line palliative chemotherapy in patients with advanced pancreatic cancer ±èÀçȯ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 15:50~16:00 Significance of reproductive factors as predictors of high risk for developing gallbladder cancer in Korean women with benign gallbladder disease ÀÌ¿ë¿ì(°æºÏÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 16:00~16:10 Comparison of Endoscopic Ultrasound-Guided Tissue Acquisition for Solid Liver Masses: Menghini Needle with a Lateral Forward Bevel vs. Franseen Needle À̽ÿµ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 16:10~16:20 Proportional Correlation Between Systemic Inflammation Response Index and Time to Gastric Cancer Recurrence Àΰæ·û(Ãæ³²ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 16:20~16:30 An Inverse Association Between Dietary ¥â-Carotene And Vitamin A Intake And Colorectal Adenoma Incidence: A Cross-Sectional Study and Meta-analysis Á¤ÁÖ¿ø(À»ÁöÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 16:30~16:40 Comparison of the prognosis and lymph node metastasis between ¡°no tumor budding¡± and ¡°low-grade tumor budding¡± in T1 and T2 colorectal cancer ÀÌÁ¾À±(µ¿¾ÆÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 16:40~16:50 Distinct Microbiome Composition and Network Formation in Saliva, Feces, and Blood of Patients with Pancreatic Cancer ±èÀçȯ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 16:50~17:00 Oral Microbiome Signatures Enable Non‑Invasive Diagnosis of Pancreatic Ductal Adenocarcinoma in Korean Patients ±èÁöÈÆ(¿¬¼¼ÀÇ´ë)

±âŸ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 17:00~17:10 ½Ã»ó½Ä ()

±âŸ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A 17:10~17:20 Æóȸ»ç ()

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 09:10~09:35 Macrophage-Derived WNT Signaling: Orchestrating Immune Suppression and Progression in Pancreatic Cancer ¼®½ÂÇõ(¼­¿ï´ë ¹Ì»ý¹°Çаú)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 09:35~10:00 Transforming DNA Data into Action with Whole Genome Insights °íÁØ¿µ(Áö³ðÀλçÀÌÆ®)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 10:00~10:25 Novel Drug Delivery Mechanism by Utilizing Stemsomes for Targeting Pancreatic Cancer °­µ¿¿ì(°¡Ãµ´ë »ý¸®Çаú)

ÈÞ½Ä 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B, Lobby 10:25~10:40 ()

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 10:40~11:05 Investigating the Relationship with MRI-based Radiomics and Next-Generation Sequencing Using Rim Enhancement of Pancreatic Ductal Adenocarcinoma À±½Â¹è(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 11:05~11:30 Comparative Efficacy of 5-Fluorouracil and Capecitabine as Adjuvant Therapies in Biliary Tract Cancer: A Comprehensive Analysis of Outcomes ÀÌŽÂ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 11:30~11:55 Survival Predictors in Pancreatic Cancer Patients on Liposomal Irinotecan Plus Fluorouracil/Leucovorin ±ÝÁö¿µ(ÀÌÈ­ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 11:55~12:20 A Novel Retractable Robotic Device for Colorectal Endoscopic Submucosal Dissection ±è»óÇö(°í·ÁÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A, B 12:20~12:50 Durvalumab: Real-World Practice in Advanced Biliary Tract Cancer ¹é¿ìÇö(¼­¿ïÀÇ´ë)

±âŸ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall A, B 12:50~13:20 ´ëÇѼÒÈ­±â¾Ï¿¬±¸ÇÐȸ ÃÑȸ ()

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 13:20~13:45 Nivolumab for Gastric Cancer: Real-World Practice °­¼±Çü(Ãæ³²ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 13:45~14:10 Novel Therapies in HER2-Positive Gastric Cancer °­¹öµé(Â÷ÀÇ°úÇдë Á¾¾ç³»°ú)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 14:10~14:35 Recent Updates in Neoadjuvant Treatment for Colon Cancer ÀÌÁ¾À±(µ¿¾ÆÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 14:35~15:00 Patient Selection and Treatment Delivery Aiming for Organ Preservation in Rectal Cancer ±èÁø¾Æ(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú)

ÈÞ½Ä 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B, Lobby 15:00~15:20 Coffee Break ()

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 15:20~15:55 µðÁöÅÐ ÀÇ·á±â¼ú¿¡¼­ÀÇ À±¸®Àû ÀïÁ¡ ±èÁØÇõ(¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ) Çʼö

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 15:55~16:30 ÀÇÇבּ¸À±¸®¿Í ÀÌÇØ»óÃæ ÀÌÀÏÇÐ(¿¬¼¼´ëÇб³ ÀÇ·á¹ýÀ±¸®Çаú) Çʼö

±³À°½Ã°£ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 16:30~17:00 Æø¾ð ¹× ³ìÃë, ÆøÇà°ü·Ã ÀÇ»çÀÇ ´ëó¿¡¼­ÀÇ ÀÇ·áÀ±¸®ÀÇ ¿ªÇÒ ¹ÚÁö¿ë(¿¬¼¼´ëÇб³ ¹ýÇдëÇÐ) Çʼö

±âŸ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 17:00~17:10 ½Ã»ó½Ä ()

±âŸ 03¿ù 30ÀÏ ±×·£µåº¼·ë Hall B 17:10~17:20 Æóȸ»ç ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѼÒÈ­±â¾Ï¿¬±¸ÇÐȸ Á¦19ȸ Ãá°èÇмú´ëȸ : 2024-03-30""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ Á¦57Â÷ Çмú´ëȸ (2ÀÏÂ÷) : 2024-03-30
´ÙÀ½±Û 2024³â ´ëÇÑÀ̽ÄÇÐȸ Á¦20Â÷ Ãá°èÇмú´ëȸ(1ÀÏÂ÷) : 2024-03-29
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20467 ¼­¿ï 2024 ´ëÇÑÇ÷¾×ÇÐȸ Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-31 0 76 2024-04-17
20466 °æ±â ¾ÆÁִ뺴¿ø ÀÀ±ÞÀÇÇаú ¼³¸³ 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-05-30 0 39 2024-04-17
20465 ¼­¿ï Á¦20Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ ÇÁ·Î±×·¥ : 2024-05-26 0 45 2024-04-17
20464 °æ±â 2024³â Á¦86Â÷ ´ëÇÑ»ý½ÄÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-26 0 34 2024-04-17
20463 ¼­¿ï 2024³â ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-05-26 0 25 2024-04-17
20462 ¼­¿ï ´ëÇÑÃæ°ÝÆÄÄ¡·áÇÐȸ 2024 Ãá°è Çмú´ëȸ : 2024-05-26 0 23 2024-04-17
20461 ¼­¿ï Áø´Ü ü°èÀû¹®Çå°íÂû ¿öÅ©¼¥ : 2024-05-25 0 30 2024-04-17
20460 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦17ȸ ODOT (One Day Course of Obesity Treatment) : 2024-05-25 0 24 2024-04-17
20459 ¼­¿ï 2024³â Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2024-05-24 0 16 2024-04-17
20458 ¼­¿ï 2024 Á¦12ȸ ´ëÇÑÇ÷¾×ÇÐȸ Ç÷¿ìº´¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-24 0 28 2024-04-17
20457 ¼­¿ï 2024³â ¿µµîÆ÷±¸ÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-05-21 0 31 2024-04-17
20456 ¼­¿ï 2024³â ´ëÇÑÀÓ»ó°Ç°­ÁõÁøÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-05-19 0 32 2024-04-17
20455 ¼­¿ï Á¦7Â÷ ´ëÇѼö¸éÈ£ÈíÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-19 0 39 2024-04-17
20454 ¼­¿ï 2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°è¿¬¼ö°­Á : 2024-05-18 0 26 2024-04-17
20453 ¼­¿ï 2024³â ´ëÇÑ¿¬ÇÏÀå¾ÖÇÐȸ Á¦14ȸ Ãá°èÇмú´ëȸ : 2024-05-18 0 31 2024-04-17
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷